Spirometrix, a Pleasanton, CA-based technology healthcare company focused on research, development and commercialization of breath analysis devices for applications in disease diagnosis and management, closed an $8.6m Series B financing.
The round was led by biosensor manufacturing partner Ngk Spark Plug Co., Ltd, which invested approximately $5m, with participation from current investor Simul Investments. As part of the financing, a member of NTK will join the Board of Directors of Spirometrix.
Founded in 2011 and led by J. Dean Zikria, CEO, Spirometrix focuses on research, development and commercialization of novel breath analysis devices for application in disease diagnosis and management for asthma, COPD, and chronic pulmonary hypertension using a nexus of consumer technologies for preventative healthcare through its proprietary set of sensors and algorithms.